Scientists track drug behavior in severe colitis patients
NCT ID NCT03765450
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the drug infliximab behaves in the body of people hospitalized with severe ulcerative colitis. Researchers measure drug levels in blood, stool, and colon tissue, along with changes in proteins and genes. The goal is to better understand how the drug works, not to test a new treatment. About 18 adults with severe colitis are taking part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE SEVERE ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cornell University
New York, New York, 10065, United States
-
Mount Sinai Hospital
Toronto, Ontario, M5G 1X5, Canada
-
UCSD
San Diego, California, 92037, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Sound waves vs. scope: a gentler way to spot pouch inflammation?
- Can we predict how kids with IBD will respond to treatment?
- Can switching IBD meds heal the gut when symptoms are quiet?
- Can a milk sugar tame IBD symptoms?
- Could an extra flu shot shield vulnerable kids?
- Can a glass of pomegranate juice tame gut inflammation?